92 Works

Detailed in vitro analyses of the impact of multimodal cancer therapy with hyperthermia and radiotherapy on the immune phenotype of human glioblastoma cells

Eileen Stoll, Michael Hader, Michael Rückert, Thomas Weissmann, Sebastian Lettmaier, Florian Putz, Markus Hecht, Rainer Fietkau, Andreas Rosin, Benjamin Frey & Udo S. Gaipl
Improvements of heat-delivery systems have led to hyperthermia (HT) being increasingly recognized as an adjunct treatment modality also for brain tumors. But how HT affects the immune phenotype of glioblastoma cells is only scarcely known. We therefore investigated the effect of in vitro HT, radiotherapy (RT), and the combination of both (RHT) on cell death modalities, immune checkpoint molecule (ICM) expression and release of the danger signal HSP70 of two human glioblastoma cell lines (U87...

Detailed in vitro analyses of the impact of multimodal cancer therapy with hyperthermia and radiotherapy on the immune phenotype of human glioblastoma cells

Eileen Stoll, Michael Hader, Michael Rückert, Thomas Weissmann, Sebastian Lettmaier, Florian Putz, Markus Hecht, Rainer Fietkau, Andreas Rosin, Benjamin Frey & Udo S. Gaipl
Improvements of heat-delivery systems have led to hyperthermia (HT) being increasingly recognized as an adjunct treatment modality also for brain tumors. But how HT affects the immune phenotype of glioblastoma cells is only scarcely known. We therefore investigated the effect of in vitro HT, radiotherapy (RT), and the combination of both (RHT) on cell death modalities, immune checkpoint molecule (ICM) expression and release of the danger signal HSP70 of two human glioblastoma cell lines (U87...

Additional file 2 of EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy

Jonas Leichsenring, Valentina Vladimirova, Christine Solbach, Thomas Karn, Beyhan Ataseven, Bruno Valentin Sinn, Jana Barinoff, Volkmar Müller, Jens-Uwe Blohmer, Christian Schem, Knut Engels, Frederik Marmé, Annette Fisseler-Eckhoff, Peter A. Fasching, Elmar Stickeler, Marion van Mackelenbergh, Carsten Denkert, Albrecht Stenzinger, Sibylle Loibl & Stefan Gröschel
Additional file 2: Supplementary Figure 2. Distribution of EVI1 continuous expression in breast cancer: A: Histogram of EVI1 continuous expression in the entire cohort (N=993); B: Boxplots of EVI1 continuous expression within breast cancer subtypes. Note, 882/993 patients with available BC subtype information were included in this analysis. Horizontal bold lines present EVI1 median values of 116.65 in HR+/HER2-, 98.67 in HR+/HER2+, 114.77in HR-/HER2+, and 115.64 in TNBC; boxes present the interquartile range between first...

EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy

Jonas Leichsenring, Valentina Vladimirova, Christine Solbach, Thomas Karn, Beyhan Ataseven, Bruno Valentin Sinn, Jana Barinoff, Volkmar Müller, Jens-Uwe Blohmer, Christian Schem, Knut Engels, Frederik Marmé, Annette Fisseler-Eckhoff, Peter A. Fasching, Elmar Stickeler, Marion van Mackelenbergh, Carsten Denkert, Albrecht Stenzinger, Sibylle Loibl & Stefan Gröschel
Abstract Background Overexpression of the EVI1 (ecotropic viral integration site 1) oncogene has recently been implicated as a prognostic factor in breast cancer (BC), particularly in triple-negative BC (TNBC). In this study we aimed to investigate frequency and clinical relevance of EVI1 expression in newly diagnosed BC treated with neoadjuvant chemotherapy. Methods EVI1 expression was determined by immunohistochemistry using H-score as a cumulative measurement of protein expression in pretherapeutic biopsies of BC patients treated with...

Digitally-supported patient-centered asynchronous outpatient follow-up in rheumatoid arthritis - an explorative qualitative study

Ramona Stenzel, Katharina Hadaschik, Susann May, Manuel Grahammer, Hannah Labinsky, Martin Welcker, Johannes Hornig, Gerlinde Bendzuck, Corinna Elling-Audersch, Ulrike Erstling, Patricia Steffens Korbanka, Nicolas Vuillerme, Martin Heinze, Gerhard Krönke, Georg Schett, Ann-Christin Pecher, Martin Krusche, Johanna Mucke, Johannes Knitza & Felix Muehlensiepen
Abstract Objective A steadily increasing demand and decreasing number of rheumatologists push current rheumatology care to its limits. Long travel times and poor accessibility of rheumatologists present particular challenges for patients. Need-adapted, digitally supported, patient-centered and flexible models of care could contribute to maintaining high-quality patient care. This qualitative study was embedded in a randomized controlled trial (TELERA) investigating a new model of care consisting of the use of a medical app for ePRO (electronic...

Additional file 11 of Efficacy and safety of guselkumab and adalimumab for pustulotic arthro-osteitis and their impact on peripheral blood immunophenotypes

Masanobu Ueno, Ippei Miyagawa, Yusuke Miyazaki, Kentaro Hanami, Shunsuke Fukuyo, Satoshi Kubo, Shingo Nakayamada & Yoshiya Tanaka
Additional file 11: Supplementary Table S6. Comparison of activated Th1 and Th17 between PPPASI-50/75/90 responder and non-responder in PAO. Data are shown by median(quartile). P values were determined by Wilcoxon rank sum test. p*<0.05: with PPPASI-50 responder (N = 14) vs non-responder (N = 7) at baseline, PPPASI-75 responder (N = 13) vs non-responder (N = 8) at baseline, PPPASI-90 responder (N = 12) vs non-responder (N = 9) at baseline, PPPASI-50/75 responder (N =...

Early remission in multiple sclerosis is linked to altered coherence of the Cerebellar Network

Marlene Tahedl, Seth M. Levine, Robert Weissert, Zacharias Kohl, De-Hyung Lee, Ralf A. Linker & Jens V. Schwarzbach
Abstract Background The development of permanent disability in multiple sclerosis (MS) is highly variable among patients, and the exact mechanisms that contribute to this disability remain unknown. Methods Following the idea that the brain has intrinsic network organization, we investigated changes of functional networks in MS patients to identify possible links between network reorganization and remission from clinical episodes in MS. Eighteen relapsing–remitting MS patients (RRMS) in their first clinical manifestation underwent resting-state functional MRI...

Additional file 1 of Early remission in multiple sclerosis is linked to altered coherence of the Cerebellar Network

Marlene Tahedl, Seth M. Levine, Robert Weissert, Zacharias Kohl, De-Hyung Lee, Ralf A. Linker & Jens V. Schwarzbach
Additional file 1: Figure S1. Probability that a given network is the “original network”, whose functional coherence is changed in MS patients following their entrance into remission. Open circles are data from individual patients; closed circles depict the mean, and error bars are SEM. (A) Results from the first set of 9 patients. (B) Results from the second set of 9 patients. Note that in both cases the cerebellar network is, by far, the most...

Additional file 2 of Structural tissue damage and 24-month progression of semi-quantitative MRI biomarkers of knee osteoarthritis in the IMI-APPROACH cohort

Frank W. Roemer, Mylène Jansen, Anne C. A. Marijnissen, Ali Guermazi, Rafael Heiss, Susanne Maschek, Agnes Lalande, Francisco J. Blanco, Francis Berenbaum, Lotte A. van de Stadt, Margreet Kloppenburg, Ida K. Haugen, Christoph H. Ladel, Jaume Bacardit, Anna Wisser, Felix Eckstein, Floris P. J. G. Lafeber, Harrie H. Weinans & Wolfgang Wirth
Additional file 2.

Additional file 3 of Association of angiotensin-converting enzyme insertion/deletion (ACE I/D) gene polymorphism with susceptibility to prostate cancer: an updated meta-analysis

Jianhui Du, Jianhua Lan, Hai Yang, Qiao Ying, Guohua Huang, Jian Mou, Jia Long, Zhenghua Qiao & Qiyi Hu
Additional file 3: Supplementary Figure 2. Funnel plot to detect potential publication bias. A: Model of allelic gene; B: Model of recessive gene inheritance; C: Model of dominant gene inheritance; D: Model of heterozygous gene inheritance; E: Model of homozygous gene inheritance.

Association of angiotensin-converting enzyme insertion/deletion (ACE I/D) gene polymorphism with susceptibility to prostate cancer: an updated meta-analysis

Jianhui Du, Jianhua Lan, Hai Yang, Qiao Ying, Guohua Huang, Jian Mou, Jia Long, Zhenghua Qiao & Qiyi Hu
Abstract Objective This meta-analysis aims to explore the association between angiotensin-converting enzyme (ACE) insertion/deletion (I/D) gene polymorphism and susceptibility to prostate cancer (PCa). Methods We searched studies related to ACE I/D polymorphism and susceptibility to PCa through PubMed, Web of Science, Embase, Cochrane Library, and Scopus databases from inception to June 1, 2022. Five gene models, including allelic, dominant, recessive, homozygote, and heterozygote models, were analyzed. The pooled odds ratio (OR) was calculated using Stata...

Additional file 11 of Efficacy and safety of guselkumab and adalimumab for pustulotic arthro-osteitis and their impact on peripheral blood immunophenotypes

Masanobu Ueno, Ippei Miyagawa, Yusuke Miyazaki, Kentaro Hanami, Shunsuke Fukuyo, Satoshi Kubo, Shingo Nakayamada & Yoshiya Tanaka
Additional file 11: Supplementary Table S6. Comparison of activated Th1 and Th17 between PPPASI-50/75/90 responder and non-responder in PAO. Data are shown by median(quartile). P values were determined by Wilcoxon rank sum test. p*<0.05: with PPPASI-50 responder (N = 14) vs non-responder (N = 7) at baseline, PPPASI-75 responder (N = 13) vs non-responder (N = 8) at baseline, PPPASI-90 responder (N = 12) vs non-responder (N = 9) at baseline, PPPASI-50/75 responder (N =...

Additional file 5 of Efficacy and safety of guselkumab and adalimumab for pustulotic arthro-osteitis and their impact on peripheral blood immunophenotypes

Masanobu Ueno, Ippei Miyagawa, Yusuke Miyazaki, Kentaro Hanami, Shunsuke Fukuyo, Satoshi Kubo, Shingo Nakayamada & Yoshiya Tanaka
Additional file 5: Figure S5. Changes in serum TNF-α and IL-17 concentration during 6 months of treatment. TNF-α (pg/ml), B. IL-17A (fg/ml). *p<0.05, by Wilcoxon signed rank test. TNF; tumor necrosis factor.

Additional file 6 of Efficacy and safety of guselkumab and adalimumab for pustulotic arthro-osteitis and their impact on peripheral blood immunophenotypes

Masanobu Ueno, Ippei Miyagawa, Yusuke Miyazaki, Kentaro Hanami, Shunsuke Fukuyo, Satoshi Kubo, Shingo Nakayamada & Yoshiya Tanaka
Additional file 6: Supplementary Table S1. Flow cytometry antibody panels used in this study.

Acute systemic knockdown of Atg7 is lethal and causes pancreatic destruction in shRNA transgenic mice

Laura Mainz, Mohamed A. F. E. Sarhan, Sabine Roth, Ursula Sauer, Charis Kalogirou, Markus Eckstein, Elena Gerhard-Hartmann, Helen-Desiree Seibert, Hans-Ulrich Voelker, Carol Geppert, Andreas Rosenwald, Martin Eilers, Almut Schulze, Markus Diefenbacher & Mathias T. Rosenfeldt
The notion that macroautophagy/autophagy is a potentially attractive therapeutic target for a variety of diseases, including cancer, largely stems from pre-clinical mouse studies. Most of these examine the effects of irreversible and organ confined autophagy deletion using site specific Cre-loxP recombination of the essential autophagy regulating genes Atg7 or Atg5. Model systems with the ability to impair autophagy systemically and reversibly at all disease stages would allow a more realistic approach to evaluate the consequences...

Acute systemic knockdown of Atg7 is lethal and causes pancreatic destruction in shRNA transgenic mice

Laura Mainz, Mohamed A. F. E. Sarhan, Sabine Roth, Ursula Sauer, Charis Kalogirou, Markus Eckstein, Elena Gerhard-Hartmann, Helen-Desiree Seibert, Hans-Ulrich Voelker, Carol Geppert, Andreas Rosenwald, Martin Eilers, Almut Schulze, Markus Diefenbacher & Mathias T. Rosenfeldt
The notion that macroautophagy/autophagy is a potentially attractive therapeutic target for a variety of diseases, including cancer, largely stems from pre-clinical mouse studies. Most of these examine the effects of irreversible and organ confined autophagy deletion using site specific Cre-loxP recombination of the essential autophagy regulating genes Atg7 or Atg5. Model systems with the ability to impair autophagy systemically and reversibly at all disease stages would allow a more realistic approach to evaluate the consequences...

Additional file 2 of Structural tissue damage and 24-month progression of semi-quantitative MRI biomarkers of knee osteoarthritis in the IMI-APPROACH cohort

Frank W. Roemer, Mylène Jansen, Anne C. A. Marijnissen, Ali Guermazi, Rafael Heiss, Susanne Maschek, Agnes Lalande, Francisco J. Blanco, Francis Berenbaum, Lotte A. van de Stadt, Margreet Kloppenburg, Ida K. Haugen, Christoph H. Ladel, Jaume Bacardit, Anna Wisser, Felix Eckstein, Floris P. J. G. Lafeber, Harrie H. Weinans & Wolfgang Wirth
Additional file 2.

Additional file 1 of EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy

Jonas Leichsenring, Valentina Vladimirova, Christine Solbach, Thomas Karn, Beyhan Ataseven, Bruno Valentin Sinn, Jana Barinoff, Volkmar Müller, Jens-Uwe Blohmer, Christian Schem, Knut Engels, Frederik Marmé, Annette Fisseler-Eckhoff, Peter A. Fasching, Elmar Stickeler, Marion van Mackelenbergh, Carsten Denkert, Albrecht Stenzinger, Sibylle Loibl & Stefan Gröschel
Additional file 1: Supplementary Figure 1. Flow diagram of patients included in the analysis set from GeparTrio study.

Additional file 2 of EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy

Jonas Leichsenring, Valentina Vladimirova, Christine Solbach, Thomas Karn, Beyhan Ataseven, Bruno Valentin Sinn, Jana Barinoff, Volkmar Müller, Jens-Uwe Blohmer, Christian Schem, Knut Engels, Frederik Marmé, Annette Fisseler-Eckhoff, Peter A. Fasching, Elmar Stickeler, Marion van Mackelenbergh, Carsten Denkert, Albrecht Stenzinger, Sibylle Loibl & Stefan Gröschel
Additional file 2: Supplementary Figure 2. Distribution of EVI1 continuous expression in breast cancer: A: Histogram of EVI1 continuous expression in the entire cohort (N=993); B: Boxplots of EVI1 continuous expression within breast cancer subtypes. Note, 882/993 patients with available BC subtype information were included in this analysis. Horizontal bold lines present EVI1 median values of 116.65 in HR+/HER2-, 98.67 in HR+/HER2+, 114.77in HR-/HER2+, and 115.64 in TNBC; boxes present the interquartile range between first...

Additional file 2 of Digitally-supported patient-centered asynchronous outpatient follow-up in rheumatoid arthritis - an explorative qualitative study

Ramona Stenzel, Katharina Hadaschik, Susann May, Manuel Grahammer, Hannah Labinsky, Martin Welcker, Johannes Hornig, Gerlinde Bendzuck, Corinna Elling-Audersch, Ulrike Erstling, Patricia Steffens Korbanka, Nicolas Vuillerme, Martin Heinze, Gerhard Krönke, Georg Schett, Ann-Christin Pecher, Martin Krusche, Johanna Mucke, Johannes Knitza & Felix Muehlensiepen
Supplementary Material 2

Additional file 3 of Digitally-supported patient-centered asynchronous outpatient follow-up in rheumatoid arthritis - an explorative qualitative study

Ramona Stenzel, Katharina Hadaschik, Susann May, Manuel Grahammer, Hannah Labinsky, Martin Welcker, Johannes Hornig, Gerlinde Bendzuck, Corinna Elling-Audersch, Ulrike Erstling, Patricia Steffens Korbanka, Nicolas Vuillerme, Martin Heinze, Gerhard Krönke, Georg Schett, Ann-Christin Pecher, Martin Krusche, Johanna Mucke, Johannes Knitza & Felix Muehlensiepen
Supplementary Material 3

Additional file 3 of EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy

Jonas Leichsenring, Valentina Vladimirova, Christine Solbach, Thomas Karn, Beyhan Ataseven, Bruno Valentin Sinn, Jana Barinoff, Volkmar Müller, Jens-Uwe Blohmer, Christian Schem, Knut Engels, Frederik Marmé, Annette Fisseler-Eckhoff, Peter A. Fasching, Elmar Stickeler, Marion van Mackelenbergh, Carsten Denkert, Albrecht Stenzinger, Sibylle Loibl & Stefan Gröschel
Additional file 3: Supplementary Figure 3. Kaplan-Meier estimates of DFS (A) and OS (B) according to EVI1 expression in the non-pCR subgroup. Abbreviations:pCR, pathological complete response; DFS, disease-free survival; OS, overallsurvival.

Additional file 4 of Efficacy and safety of guselkumab and adalimumab for pustulotic arthro-osteitis and their impact on peripheral blood immunophenotypes

Masanobu Ueno, Ippei Miyagawa, Yusuke Miyazaki, Kentaro Hanami, Shunsuke Fukuyo, Satoshi Kubo, Shingo Nakayamada & Yoshiya Tanaka
Additional file 4: Figure S4. Impact of adalimumab treatment on peripheral blood immune phenotypes. Changes in the proportion of A. CD4+ T cells subsets to CD3+ and CD4+ T cells (%), B. CD8+ T cells subsets to CD3+ and CD8+ T cells (%), C. a)-c) Activated CD4+ T cells to CD3+ and CD4+ T cells (%) d) Activated CD8+ T cells to CD3+ and CD8+ T cells (%), D. B cells subsets to CD3- and...

Additional file 4 of Efficacy and safety of guselkumab and adalimumab for pustulotic arthro-osteitis and their impact on peripheral blood immunophenotypes

Masanobu Ueno, Ippei Miyagawa, Yusuke Miyazaki, Kentaro Hanami, Shunsuke Fukuyo, Satoshi Kubo, Shingo Nakayamada & Yoshiya Tanaka
Additional file 4: Figure S4. Impact of adalimumab treatment on peripheral blood immune phenotypes. Changes in the proportion of A. CD4+ T cells subsets to CD3+ and CD4+ T cells (%), B. CD8+ T cells subsets to CD3+ and CD8+ T cells (%), C. a)-c) Activated CD4+ T cells to CD3+ and CD4+ T cells (%) d) Activated CD8+ T cells to CD3+ and CD8+ T cells (%), D. B cells subsets to CD3- and...

Additional file 7 of Efficacy and safety of guselkumab and adalimumab for pustulotic arthro-osteitis and their impact on peripheral blood immunophenotypes

Masanobu Ueno, Ippei Miyagawa, Yusuke Miyazaki, Kentaro Hanami, Shunsuke Fukuyo, Satoshi Kubo, Shingo Nakayamada & Yoshiya Tanaka
Additional file 7: Supplementary Table S2. Comparison of activated Th1 and Th17 at baseline between with DMARDs group (N = 16) and without DMARDs group (N = 6). Data are shown by median(quartile) or n (%). P values were determined by the Wilcoxon rank sum test. p*<0.05: with DMARDs (N = 16) vs without DMARDs (N = 6).

Registration Year

  • 2022
    92

Resource Types

  • Text
    64
  • Collection
    14
  • Audiovisual
    6
  • Dataset
    4
  • Image
    4

Affiliations

  • Universitätsklinikum Erlangen
    92
  • University of Erlangen-Nuremberg
    42
  • University Medical Center Hamburg-Eppendorf
    26
  • Leiden University Medical Center
    26
  • University of Occupational and Environmental Health Japan
    21
  • Hôpital Saint-Antoine
    20
  • Newcastle University
    20
  • University of A Coruña
    20
  • Diakonhjemmet Hospital
    20
  • Servier (France)
    20